Application 217590
- Type
- ANDA
- Sponsor
- ORBICULAR
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LIRAGLUTIDE | LIRAGLUTIDE | SOLUTION;SUBCUTANEOUS | 18MG/3ML (6MG/ML) | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A217590-001 | LIRAGLUTIDE | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION / SUBCUTANEOUS | AP1 | 2026-01-14 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A217590-001 | AP1 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A217590-001 | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION / SUBCUTANEOUS | AP1 | 2026-01-14 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A217590-001 | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION / SUBCUTANEOUS | AP1 | 2026-01-14 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A217590-001 | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION / SUBCUTANEOUS | AP1 | 2026-01-14 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217590-001 | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION / SUBCUTANEOUS | AP1 | 2026-01-14 | 011fe1cb6892… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217590-001 | LIRAGLUTIDE | 18MG/3ML (6MG/ML) | SOLUTION / SUBCUTANEOUS | AP1 | 2026-01-14 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A217590-001 | AP1 | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A217590-001 | AP1 | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A217590-001 | AP1 | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A217590-001 | AP1 | 1 | 011fe1cb6892… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217590-001 | AP1 | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Liraglutide | LIRAGLUTIDE | Meitheal Pharmaceuticals Inc. | 0efc3a89-211a-4496-baab-e8265e07de2b | 2026-07-27 | Boxed warning, Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | NorthStar Rx LLC | 4253be3b-bda6-4efd-8118-9c9538168a88 | 2026-06-24 | Boxed warning, Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| liraglutide | LIRAGLUTIDE | Cipla USA Inc. | 22c86976-9657-4dd0-8fff-0c3f3f08357c | 2026-06-18 | Boxed warning, Warnings, Adverse reactions | liraglutide LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | Hikma Pharmaceuticals USA Inc. | 2100ec49-57b2-4330-ab5f-057ce9b7e4d0 | 2026-05-14 | Boxed warning, Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | Teva Pharmaceuticals, Inc. | 625ac780-70a9-41e4-a892-bcba0f803f1c | 2026-02-27 | Boxed warning, Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Saxenda | LIRAGLUTIDE | Novo Nordisk Pharmaceutical Industries, LP | 3946d389-0926-4f77-a708-0acb8153b143 | 2026-02-25 | Boxed warning, Warnings, Adverse reactions | LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | Teva Pharmaceuticals USA, Inc. | 14bf9812-14ee-46ce-93b1-686e4906cbbc | 2026-01-30 | Boxed warning, Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | Lupin Pharmaceuticals, Inc. | 0450d8a2-a88e-4849-9788-ed4f5246f223 | 2025-11-13 | Boxed warning, Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | Biocon Pharma Inc. | 0b898330-eca1-f60a-71d2-b91716e336ed | 2025-10-16 | Boxed warning, Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Victoza | LIRAGLUTIDE | Novo Nordisk | 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 | 2025-10-14 | Boxed warning, Warnings, Adverse reactions | LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | Biocon Pharma Inc. | cb032379-043b-443c-d552-b5d25f27f3c4 | 2025-10-10 | Boxed warning, Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | A-S Medication Solutions | 0ba917f7-b974-4364-a745-7494ecae3e73 | 2025-01-30 | Boxed warning, Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 1a372465-d56b-2b80-e063-6394a90a3304 | 2024-12-03 | Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 1a36f43f-d734-97cc-e063-6294a90ae0da | 2024-12-02 | Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Liraglutide | LIRAGLUTIDE | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | 1a36b801-41e2-2eed-e063-6294a90a6f27 | 2024-06-05 | Warnings, Adverse reactions | Liraglutide LIRAGLUTIDE |
| Saxenda | LIRAGLUTIDE | A-S Medication Solutions | 7b11f6ac-4c27-4748-9e65-22d4cf3adfb4 | 2024-01-26 | Boxed warning, Warnings, Adverse reactions | LIRAGLUTIDE |
| Victoza | LIRAGLUTIDE | A-S Medication Solutions | 1d18f106-0584-4fee-97ab-32771a64b809 | 2023-02-06 | Boxed warning, Warnings, Adverse reactions | LIRAGLUTIDE |
| Victoza | LIRAGLUTIDE | A-S Medication Solutions | 35e613e3-7aae-4152-b827-99d1ee7841be | 2023-02-06 | Boxed warning, Warnings, Adverse reactions | LIRAGLUTIDE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.